Amgen Inc. (LON:0R0T)

London flag London · Delayed Price · Currency is GBP · Price in USD
374.37
-0.47 (-0.13%)
At close: Feb 20, 2026
Market Cap149.73B +13.3%
Revenue (ttm)27.31B +10.0%
Net Income5.73B +88.5%
EPS10.57 +88.2%
Shares Outn/a
PE Ratio26.13
Forward PE16.72
Dividend7.22 (1.93%)
Ex-Dividend DateFeb 13, 2026
Volume483
Average Volume1,953
Open377.53
Previous Close374.84
Day's Range372.00 - 382.47
52-Week Range259.01 - 390.00
Beta0.45
RSI63.01
Earnings DateFeb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1980
Employees 31,500
Stock Exchange London Stock Exchange
Ticker Symbol 0R0T
Full Company Profile

Financial Performance

In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.

Financial numbers in USD Financial Statements